Scalper1 News
As expected, Valeant Pharmaceuticals International (VRX) raised its hostile bid for fellow drugmaker Allergan (AGN) Wednesday morning and offered Allergan investors a lengthy defense of its business model. The market was unimpressed, however, and during morning trading in the stock market today Allergan stock was down more than 4% and Valeant stock down more than 3%. Valeant added $10 a share in cash to its original offer of $48.30 plus 0.83 of a Scalper1 News
Scalper1 News